Celcuity Inc.: peers
Celcuity Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Vitaspring Biomedical Co. Ltd.: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Celcuity Inc.base CELC · 🇺🇸 US Percentile in Healthcare Percentile in USA | CareDx, Inc CDNA · 🇺🇸 US Percentile in Healthcare Percentile in USA | Vitaspring Biomedical Co. Ltd. VSBC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Neogen Corporation NEOG · 🇺🇸 US Percentile in Healthcare Percentile in USA | BillionToOne, Inc. BLLN · 🇺🇸 US Percentile in Healthcare Percentile in USA | Sotera Health Company SHC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Grail, Inc. GRAL · 🇺🇸 US Percentile in Healthcare Percentile in USA | NeoGenomics, Inc. NEO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $3.5 BOct 5, 2026 · Market data4th of 8 | $3.4 BOct 19, 2026 · Market data5th of 8 | $3.1 Blast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 8 | $2.6 BOct 23, 2026 · Market data7th of 8 | $5.1 BOct 1, 2026 · Market data3rd of 8 | $5.2 BSep 24, 2026 · Market data2nd of 8 | $5.3 BOct 19, 2026 · Market data1st of 8 | $2.2 BOct 15, 2026 · Market data8th of 8 | $3.5 B8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $380 MFY2025 · SEC4th of 6 | —— | $870 MFY2025 · SEC2nd of 6 | $305 MFY2025 · SEC5th of 6 | $1.2 BFY2025 · SEC1st of 6 | $147 MFY2025 · SEC6th of 6 | $727 MFY2025 · SEC3rd of 6 | $554 M6 ranked |
| Net income (Higher is better) | $-177 MFY2025 · SEC7th of 8 | $-21 MFY2025 · SEC5th of 8 | $-0 MFY2025 · SEC3rd of 8 | $-8 MFY2025 · SEC4th of 8 | $7 MFY2025 · SEC2nd of 8 | $78 MFY2025 · SEC1st of 8 | $-408 MFY2025 · SEC8th of 8 | $-108 MFY2025 · SEC6th of 8 | $-15 M8 ranked |
| Employees (Better neither way: ranked highest first) | 155December 31, 2025 · Profile7th of 7 | 645As on 2021 · Profile5th of 7 | —— | 2,640As on 2023 · Profile2nd of 7 | 713December 31, 2025 · Profile4th of 7 | 3,000As on 2022 · Profile1st of 7 | 490As on 2020 · Profile6th of 7 | 2,000As on 2021 · Profile3rd of 7 | 7137 ranked |
| Growth | |||||||||
| Market cap change, 30 days (Higher is better) | —— | +4.3%30 days to Oct 19, 2026 · Market data1st of 2 | —— | -12.9%30 days to Oct 23, 2026 · Market data2nd of 2 | —— | —— | —— | —— | -4.3%2 ranked |
| Revenue growth (Higher is better) | ———— | +13.8%FY2025 · SEC3rd of 657th69th | ———— | -2.7%FY2025 · SEC6th of 621st22nd | +100.0%FY2025 · SEC1st of 691st96th | +5.7%FY2025 · SEC5th of 639th48th | +17.2%FY2025 · SEC2nd of 663rd75th | +10.1%FY2025 · SEC4th of 650th62nd | +11.9%6 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | +5.7%FY2025 · SEC3rd of 544th55th | ———— | +1.9%FY2025 · SEC5th of 532nd40th | ———— | +5.0%FY2025 · SEC4th of 542nd53rd | +38.4%FY2025 · SEC1st of 585th94th | +12.6%FY2025 · SEC2nd of 559th75th | +5.7%5 ranked |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | ———— | ———— | +68.8%FY2025 · SEConly one with it83rd85th | ———— | ———— | +68.8%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | ———— | 46.9%FY2025 · SEC3rd of 433rd60th | 68.3%FY2025 · SEC1st of 465th81st | 55.5%FY2025 · SEC2nd of 445th69th | ———— | 43.2%FY2025 · SEC4th of 427th55th | 51.2%4 ranked |
| Operating margin (Higher is better) | ———— | -8.1%FY2025 · SEC3rd of 550th29th | ———— | -2.5%FY2025 · SEC2nd of 554th36th | 5.3%FY2025 · SEC1st of 565th56th | ———— | -382.0%FY2025 · SEC5th of 58th3rd | -15.9%FY2025 · SEC4th of 543rd23rd | -8.1%5 ranked |
| Net margin (Higher is better) | ———— | -5.6%FY2025 · SEC4th of 653rd32nd | ———— | -0.9%FY2025 · SEC3rd of 658th40th | 2.4%FY2025 · SEC2nd of 665th52nd | 6.7%FY2025 · SEC1st of 673rd66th | -277.5%FY2025 · SEC6th of 612th4th | -14.8%FY2025 · SEC5th of 645th24th | -3.3%6 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | ———— | 3.7%FY2025 · SEC3rd of 560th48th | 5.2%FY2025 · SEC2nd of 563rd54th | 12.8%FY2025 · SEC1st of 577th76th | -203.8%FY2025 · SEC5th of 515th5th | -3.0%FY2025 · SEC4th of 548th28th | 3.7%5 ranked |
| Return on equity (Higher is better) | -163.8%FY2025 · SEC7th of 714th6th | -6.3%FY2025 · SEC4th of 769th36th | ———— | -0.4%FY2025 · SEC3rd of 772nd41st | 6.5%FY2025 · SEC2nd of 777th54th | 15.4%FY2025 · SEC1st of 787th79th | -16.1%FY2025 · SEC6th of 762nd30th | -12.4%FY2025 · SEC5th of 765th32nd | -6.3%7 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | 26.1×price Oct 19, 2026 · Market data3rd of 344th66th | ———— | ———— | 103.0×price Oct 1, 2026 · Market data1st of 389th95th | 30.1×price Sep 24, 2026 · Market data2nd of 350th71st | ———— | ———— | 30.1×3 ranked |
| Price to sales (Better neither way: ranked highest first) | ———— | 6.8×price Oct 19, 2026 · Market data3rd of 664th83rd | ———— | 3.0×price Oct 23, 2026 · Market data5th of 643rd60th | 11.6×price Oct 1, 2026 · Market data2nd of 676th91st | 4.3×price Sep 24, 2026 · Market data4th of 653rd72nd | 31.8×price Oct 19, 2026 · Market data1st of 688th96th | 2.8×price Oct 15, 2026 · Market data6th of 641st58th | 5.5×6 ranked |
| Price to book (Better neither way: ranked highest first) | 35.2×price Oct 5, 2026 · Market data1st of 796th98th | 11.1×price Oct 19, 2026 · Market data2nd of 786th91st | ———— | 1.3×price Oct 23, 2026 · Market data7th of 724th29th | 10.6×price Oct 1, 2026 · Market data3rd of 784th90th | 8.6×price Sep 24, 2026 · Market data4th of 781st87th | 2.0×price Oct 19, 2026 · Market data6th of 738th49th | 2.6×price Oct 15, 2026 · Market data5th of 744th57th | 8.6×7 ranked |
| Free cash flow yield (Higher is better) | -4.3%price Oct 5, 2026 · Market data6th of 756th28th | -0.2%price Oct 19, 2026 · Market data4th of 767th36th | ———— | 1.2%price Oct 23, 2026 · Market data2nd of 773rd42nd | 0.3%price Oct 1, 2026 · Market data3rd of 769th38th | 2.9%price Sep 24, 2026 · Market data1st of 778th52nd | -5.7%price Oct 19, 2026 · Market data7th of 752nd26th | -1.0%price Oct 15, 2026 · Market data5th of 765th34th | -0.2%7 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | 1.4×FY2025 · SEC4th of 583rd77th | ———— | ———— | 0.4×FY2025 · SEC2nd of 546th36th | 0.1×FY2025 · SEC1st of 523rd16th | 3.5×FY2025 · SEC5th of 593rd92nd | ———— | 0.4×FY2025 · SEC3rd of 548th38th | 0.4×5 ranked |
| Net debt to EBITDA (Lower is better) | ———— | ———— | ———— | 6.4×FY2025 · SEC2nd of 290th89th | -19.1×FY2025 · SEC1st of 21st0th | ———— | ———— | ———— | -6.4×2 ranked |
| Interest cover (Higher is better) | -12.0×FY2025 · SEC2nd of 240th20th | ———— | ———— | -0.9×FY2025 · SEC1st of 267th43rd | ———— | ———— | ———— | ———— | -6.4×2 ranked |
| Piotroski F-score (Higher is better) | —— | —— | —— | 6 of 9FY2025 · SEC2nd of 4 | 7 of 9FY2025 · SEC1st of 4 | 6 of 9FY2025 · SEC2nd of 4 | —— | 4 of 9FY2025 · SEC4th of 4 | 6.0 of 94 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 2 of 15FY2025 · Scorecard8th of 8 | 9 of 21FY2025 · Scorecard4th of 8 | 1 of 7FY2025 · Scorecard7th of 8 | 6 of 23FY2025 · Scorecard6th of 8 | 8 of 17FY2025 · Scorecard3rd of 8 | 12 of 18FY2025 · Scorecard1st of 8 | 7 of 17FY2025 · Scorecard5th of 8 | 11 of 20FY2025 · Scorecard2nd of 8 | 42% passed8 ranked |
| Valuation checks (Higher is better) | 0 of 4FY2025 · Scorecard6th of 7 | 1 of 5FY2025 · Scorecard4th of 7 | —— | 2 of 5FY2025 · Scorecard1st of 7 | 0 of 5FY2025 · Scorecard6th of 7 | 2 of 5FY2025 · Scorecard1st of 7 | 1 of 5FY2025 · Scorecard4th of 7 | 2 of 5FY2025 · Scorecard1st of 7 | 20% passed7 ranked |
| Growth checks (Higher is better) | 0 of 2FY2025 · Scorecard6th of 8 | 4 of 6FY2025 · Scorecard5th of 8 | 0 of 2FY2025 · Scorecard6th of 8 | 0 of 6FY2025 · Scorecard6th of 8 | 2 of 2FY2025 · Scorecard1st of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 3 of 4FY2025 · Scorecard4th of 8 | 4 of 5FY2025 · Scorecard3rd of 8 | 71% passed8 ranked |
| Profitability checks (Higher is better) | 0 of 3FY2025 · Scorecard6th of 8 | 1 of 5FY2025 · Scorecard4th of 8 | 0 of 2FY2025 · Scorecard6th of 8 | 0 of 5FY2025 · Scorecard6th of 8 | 2 of 3FY2025 · Scorecard1st of 8 | 2 of 3FY2025 · Scorecard1st of 8 | 1 of 4FY2025 · Scorecard3rd of 8 | 1 of 5FY2025 · Scorecard4th of 8 | 20% passed8 ranked |
| Financial health checks (Higher is better) | 2 of 5FY2025 · Scorecard6th of 8 | 2 of 3FY2025 · Scorecard3rd of 8 | 0 of 2FY2025 · Scorecard8th of 8 | 3 of 6FY2025 · Scorecard5th of 8 | 4 of 5FY2025 · Scorecard1st of 8 | 1 of 3FY2025 · Scorecard7th of 8 | 2 of 3FY2025 · Scorecard3rd of 8 | 3 of 4FY2025 · Scorecard2nd of 8 | 58% passed8 ranked |
| Shareholder returns checks (Higher is better) | 0 of 1FY2025 · Scorecard6th of 8 | 1 of 2FY2025 · Scorecard5th of 8 | 1 of 1FY2025 · Scorecard1st of 8 | 1 of 1FY2025 · Scorecard1st of 8 | 0 of 2FY2025 · Scorecard6th of 8 | 1 of 1FY2025 · Scorecard1st of 8 | 0 of 1FY2025 · Scorecard6th of 8 | 1 of 1FY2025 · Scorecard1st of 8 | 75% passed8 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 117.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 99.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | —— | 105.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 38.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 98.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 84.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | 110.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 99.0%7 ranked |
| Institutions holding (Better neither way: ranked highest first) | 2692026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | 3082026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | —— | 3382026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 1722026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 3482026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 4472026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 2972026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 3087 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | +14.9 pp2026-Q2 against 2026-Q1 · 13F1st of 6 | +1.5 pp2026-Q2 against 2026-Q1 · 13F6th of 6 | —— | +1.9 pp2026-Q2 against 2026-Q1 · 13F5th of 6 | —— | +6.7 pp2026-Q2 against 2026-Q1 · 13F3rd of 6 | +1.9 pp2026-Q2 against 2026-Q1 · 13F4th of 6 | +9.8 pp2026-Q2 against 2026-Q1 · 13F2nd of 6 | +4.3 pp6 ranked |
| Dividends | |||||||||
| Shareholder yield (Higher is better) | ———— | 2.6%FY2025 · SEC1st of 255th43rd | ———— | ———— | 0.0%FY2025 · SEC2nd of 27th3rd | ———— | ———— | ———— | 1.3%2 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Celcuity Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CareDx, Inc: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Vitaspring Biomedical Co. Ltd.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Neogen Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; BillionToOne, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Sotera Health Company: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Grail, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; NeoGenomics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Celcuity Inc. | — | — | — |
| CareDx, Inc | -8.1%FY2025 | 50th percentile in Healthcaremedian -7.7%, 674 companies | 29th percentile in USAmedian 3.5%, 2,594 companies |
| Vitaspring Biomedical Co. Ltd. | — | — | — |
| Neogen Corporation | -2.5%FY2025 | 54th percentile in Healthcaremedian -7.7%, 674 companies | 36th percentile in USAmedian 3.5%, 2,594 companies |
| BillionToOne, Inc. | 5.3%FY2025 | 65th percentile in Healthcaremedian -7.7%, 674 companies | 56th percentile in USAmedian 3.5%, 2,594 companies |
| Sotera Health Company | — | — | — |
| Grail, Inc. | -382.0%FY2025 | 8th percentile in Healthcaremedian -7.7%, 674 companies | 3rd percentile in USAmedian 3.5%, 2,594 companies |
| NeoGenomics, Inc. | -15.9%FY2025 | 43rd percentile in Healthcaremedian -7.7%, 674 companies | 23rd percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Celcuity Inc. | CareDx, Inc | Vitaspring Biomedical Co. Ltd. | Neogen Corporation | BillionToOne, Inc. | Sotera Health Company | Grail, Inc. | NeoGenomics, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | $380 MSEC4th | — | $870 MSEC2nd | $305 MSEC5th | $1.2 BSEC1st | $147 MSEC6th | $727 MSEC3rd |
| 2024 | — | $334 MSEC4th | — | $895 MSEC2nd | $153 MSEC5th | $1.1 BSEC1st | $126 MSEC6th | $661 MSEC3rd |
| 2023 | — | $280 MSEC4th | — | $924 MSEC2nd | $72 MSEC6th | $1.0 BSEC1st | $93 MSEC5th | $592 MSEC3rd |
| 2022 | — | $322 MSEC4th | — | $822 MSEC2nd | — | $1.0 BSEC1st | $56 MSEC5th | $510 MSEC3rd |
| 2021 | — | $296 MSEC4th | $6 MSEC5th | $527 MSEC2nd | — | $931 MSEC1st | — | $484 MSEC3rd |
| 2020 | — | $192 MSEC4th | $0 MSEC5th | $468 MSEC2nd | — | $818 MSEC1st | — | $444 MSEC3rd |
| 2019 | — | $127 MSEC4th | $0 MSEC5th | $418 MSEC2nd | — | $778 MSEC1st | — | $409 MSEC3rd |
| 2018 | — | $77 MSEC3rd | $0 MSEC4th | $414 MSEC1st | — | — | — | $277 MSEC2nd |
| 2017 | — | $48 MSEC3rd | $0 MSEC4th | $398 MSEC1st | — | — | — | $240 MSEC2nd |
| 2016 | — | $41 MSEC3rd | — | $358 MSEC1st | — | — | — | $232 MSEC2nd |
| 2015 | — | $28 MSEC3rd | — | $321 MSEC1st | — | — | — | $100 MSEC2nd |
| 2014 | — | $27 MSEC3rd | — | $283 MSEC1st | — | — | — | $87 MSEC2nd |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Celcuity Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- CareDx, IncCDNA · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $3.4 B market cap against $3.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $3.4 B (Oct 19, 2026) · revenue $380 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Vitaspring Biomedical Co. Ltd.VSBC · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $3.1 B market cap against $3.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $3.1 B (last known, Jan 5, 2024)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Neogen CorporationNEOG · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $2.6 B market cap against $3.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $2.6 B (Oct 23, 2026) · revenue $870 M (year to May 2026)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- BillionToOne, Inc.BLLN · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $5.1 B market cap against $3.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $5.1 B (Oct 1, 2026) · revenue $305 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Sotera Health CompanySHC · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $5.2 B market cap against $3.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $5.2 B (Sep 24, 2026) · revenue $1.2 B (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Grail, Inc.GRAL · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $5.3 B market cap against $3.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $5.3 B (Oct 19, 2026) · revenue $147 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- NeoGenomics, Inc.NEO · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $2.2 B market cap against $3.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $2.2 B (Oct 15, 2026) · revenue $727 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- RadNet, Inc.RDNT · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $5.8 B market cap against $3.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $5.8 B (Oct 28, 2026) · revenue $2.0 B (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Caris Life Sciences, Inc.CAI · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $6.2 B market cap against $3.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $6.2 B (Aug 1, 2026) · revenue $812 M (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)+ Add
- Fortrea Holdings Inc.FTRE · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $2.0 B market cap against $3.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $2.0 B (Oct 9, 2026) · revenue $2.7 B (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)+ Add
- Lantheus Holdings, Inc.LNTH · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $6.5 B market cap against $3.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $6.5 B (Oct 26, 2026) · revenue $1.5 B (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)+ Add
- Freenome, Inc.FRNM · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $1.7 B market cap against $3.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $1.7 B (Oct 2, 2026)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.